This is the talk page for discussing improvements to the Panitumumab article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
![]() | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
|
![]() | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Panitumumab.
|
Untitled
editThis is a brand new drug (just licenced in spetember 2006) similar to cetuximab, infact in theory it should be better. I will try and develop it when i have some time, but it would be silly to delete it. It is certainly not spam.StephP 23:29, 14 October 2006 (UTC)
- I agree, it is notable, see [1]. Lincher 16:15, 20 October 2006 (UTC)
I think panitumumab is IgG2, not IgG1. Could the author please check? Thanks.
News to incorporate
editAmgen's Vectibix effective in difficult-to-treat wild-type KRAS mCRC patients and extra background info - Rod57 (talk) 23:29, 25 January 2016 (UTC)